Ct-based intravenous thrombolysis 3- 4.5 hours after acute ischemic stroke in clinical practice

Neurological Research

Volumn 33, Issue 7, 2011, Pages 701-707

  Sarikaya, Hakan ^a   Fischer, Andrea ^a   Valko, Philipp O ^a   Weck, Anja ^a   Braun, Julia ^b   Georgiadis, Dimitrios ^a   Baumgartner, Ralf W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CT; Infarction; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT;

ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; OBSERVATIONAL STUDY; PATIENT SELECTION; PROSPECTIVE STUDY; RANKIN SCALE; RISK ASSESSMENT; SMOKING; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960499353     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000002     Document Type: Article

References (20)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
2. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
3. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004;33:116-21.
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359;1317-29.
6. Nedeltchev K, Arnold M, Brekenfeld C, Isenegger J,Remonda. L, Schroth G, et al.Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke 2003;34:1230-4.
7. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009;40:2438-2441.
8. Wahlgren N, Ahmed N, Davalos A, Hacke W,Millán M,Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372: 1303-9.
9. Uyttenboogaart M, Vroomen PC, Stewart RE, de Keyser J, Luijckx GJ. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 2007;254:28-32.
10. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41.
11. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-9.
12. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007;68:737-42.
13. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-18.
14. Tanne D,Kasner SE,Demchuk AM,Koren-Morag N,Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-85
15. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
16. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004;91:1146-51.
17. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, de Keyser J, Luijckx GJ. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 2008;65:607-11.
18. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316-22.
19. Rothwell PM, Coull AJ, Silver LE, Fairhead JF. Populationbased study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773-83.
20. Whiteley W, Lindley R, Wardlaw J, Sandercock P. Third international stroke trial. Int J Stroke 2006;1:172-6.